Fidaxomicin

Active ingredient: Fidaxomicin

In short: Fidaxomicin tablets are indicated in adult patients for the treatment of C. difficile-associated diarrhea (CDAD).

Forms & strengthsFidaxomicin tablets, 200 mg, white to off-white, modified capsule shaped, film-coated tablet debossed with “54” on one side and “26” on the other side.
LabelHikma Pharmceuticals USA Inc.
Label updatedOct 12, 2026

What is Fidaxomicin used for?

Fidaxomicin tablets are indicated in adult patients for the treatment of C. difficile-associated diarrhea (CDAD).

To reduce the development of drug-resistant bacteria and maintain the effectiveness of fidaxomicin and other antibacterial drugs, fidaxomicin tablets should be used only to treat infections that are proven or strongly suspected to be caused by C. difficile. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Pediatric use information is approved for Cubist Pharmaceuticals LLC’s DIFICID® (fidaxomicin) tablets. However, due to Cubist Pharmaceuticals LLC’s marketing exclusivity rights, this drug product is not labeled with that information.

Fidaxomicin dosage

Fidaxomicin tablets are available for oral administration as 200 mg tablets. Fidaxomicin tablets are administered orally with or without food.

The recommended dosage for adults is one 200 mg fidaxomicin tablet orally twice daily for 10 days.

Pediatric use information is approved for Cubist Pharmaceuticals LLC’s DIFICID® (fidaxomicin) tablets. However, due to Cubist Pharmaceuticals LLC’s marketing exclusivity rights, this drug product is not labeled with that information.

How to take Fidaxomicin — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Administration with Food

Inform patients and caregivers that fidaxomicin tablets may be taken with or without food.

Antibacterial Resistance

Patients should be counseled that antibacterial drugs, including fidaxomicin tablets, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When fidaxomicin tablets are prescribed to treat a C. difficile infection, patients should be told that, although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by fidaxomicin tablets or other antibacterial drugs in the future.

The trademarks depicted herein are owned by their respective companies.

Distributed by:

Hikma Pharmaceuticals, USA Inc.

Berkeley Heights, NJ 07922

C50001449/03

Revised September 2026

Warnings & precautions

Do not take this medicine if: Fidaxomicin is contraindicated in patients who have known hypersensitivity to fidaxomicin or any other ingredient in fidaxomicin tablets .

Acute hypersensitivity reactions, including dyspnea, rash, pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin. If a severe hypersensitivity reaction occurs, fidaxomicin should be discontinued and appropriate therapy should be instituted.

Some patients with hypersensitivity reactions to fidaxomicin also reported a history of allergy to other macrolides. Physicians prescribing fidaxomicin to patients with a known macrolide allergy should be aware of the possibility of hypersensitivity reactions.

Fidaxomicin is not expected to be effective for the treatment of other types of infections due to minimal systemic absorption of fidaxomicin . Fidaxomicin has not been studied for the treatment of infections other than CDAD. Fidaxomicin should only be used for the treatment of CDAD.

Prescribing fidaxomicin in the absence of proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Fidaxomicin side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adults

The safety of fidaxomicin tablets 200 mg tablets taken twice a day for 10 days was evaluated in 564 adult patients with CDAD in two active-controlled trials with 86.7% of patients receiving a full course of treatment.

Thirty-three adult patients receiving fidaxomicin (5.9%) withdrew from trials as a result of adverse reactions (AR). The types of AR resulting in withdrawal from the study varied considerably. Vomiting was the primary adverse reaction leading to discontinuation of dosing; this occurred at an incidence of 0.5% in both the fidaxomicin and vancomycin patients in Phase 3 trials. The most common selected adverse reactions occurring in ≥2% of adult patients treated with fidaxomicin are listed in Table 2. …

Drug interactions

Fidaxomicin and its main metabolite, OP-1118, are substrates of the efflux transporter, P-glycoprotein (P-gp), which is expressed in the gastrointestinal tract.

Cyclosporine is an inhibitor of multiple transporters, including P-gp. When cyclosporine was co-administered with fidaxomicin, plasma concentrations of fidaxomicin and OP-1118 were significantly increased but remained in the ng/mL range . Concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) via P-gp inhibition; however, concomitant P-gp inhibitor use had no attributable effect on safety or treatment outcome of fidaxomicin-treated adult patients in controlled clinical trials. Based on these results, fidaxomicin may be co-administered with P-gp inhibitors and no dose adjustment is recommended.

About this medicine

Fidaxomicin is a macrolide antibacterial drug for oral administration. Its chemical name is:

Oxacyclooctadeca-3,5,9,13,15-pentaene-2-one,3-[[[6-deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-β-D-mannopyranosyl]oxy]-methyl]-12-[[6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-β-D-lyxo-hexopyranosyl]oxy]-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-, (3E, 5E, 8S, 9E, 11S, 12R, 13E, 15E, 18S)-.

Structural Formula of Fidaxomicin:

Molecular formula: C52H74Cl2O18

Molecular weight: 1058.04

Fidaxomicin tablets are film-coated and contain 200 mg of fidaxomicin per tablet and the following inactive ingredients: butylated hydroxytoluene, hydroxypropyl cellulose, lecithin (soy), magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, pregelatinized starch, sodium starch glycolate, talc, and titanium dioxide.

How it works: Fidaxomicin is an antibacterial drug . Fidaxomicin acts locally in the gastrointestinal tract on C. difficile.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d773c5ee-9361-49b0-871b-af34f3f936be. Read the full official label on DailyMed.